FOCUS on Drug Approvals. On June 23rd, the FDA approved datopotamab deruxtecan-dlnk (AstraZeneca and Daiichi Sankyo’s Datroway) for non-small cell lung cancer. The antibody-drug conjugate (or
FOCUS on Drug Approvals. On June 11th, the FDA approved Taletrectinib (Ibtrozi, Nuvation Bio Inc) for adults with locally advanced or metastatic, ROS1-positive, non-small cell lung
FOCUS on Drug MOA. The mechanism of action of acetaminophen has been determined by a group led by Avi Priel at the Hebrew University, Jerusalem, and
Focus Biomolecules will be exhibiting at the annual meeting of American Association for Cancer Research in Chicago, April 27 – 30. Stop by our booth (#1004)
FOCUS on drug failures. Denali Therapeutics‘ experimental drug for Amyotrophic Lateral Sclerosis (ALS) has taken another setback as the drug generated disappointing results in a phase
Focus on Drug Discovery. Lilly will acquire Scorpion Therapeutics’ PI3Kalpha inhibitor program which includes STX-478, a potentially best-in-class mutant-selective PI3Kα inhibitor currently being evaluated in a
BOGO
